Palvella submits FDA NDA for QTORIN gel
Share
Palvella Therapeutics (NASDAQ:PVLA) said it has submitted the first module of a rolling New Drug Application to the U.S. Food and Drug Administration for QTORIN 3.9% rapamycin gel.
Palvella Therapeutics (NASDAQ:PVLA) said it has submitted the first module of a rolling New Drug Application to the U.S. Food and Drug Administration for QTORIN 3.9% rapamycin gel.
